207 related articles for article (PubMed ID: 26927556)
41. IDH1 gene mutation activates Smad signaling molecules to regulate the expression levels of cell cycle and biological rhythm genes in human glioma U87‑MG cells.
Gao Y; Wu Y; Zhang N; Yuan H; Wang F; Xu H; Yu J; Ma J; Hou S; Cao X
Mol Med Rep; 2021 May; 23(5):. PubMed ID: 33760141
[TBL] [Abstract][Full Text] [Related]
42. Pathologic diversity of glioneuronal tumor with neuropil-like islands: a histological and immunohistochemical study with a special reference to isocitrate dehydrogenase 1 (IDH1) in 5 cases.
Ishizawa K; Hirose T; Sugiyama K; Kageji T; Nobusawa S; Homma T; Komori T; Sasaki A
Clin Neuropathol; 2012; 31(2):67-76. PubMed ID: 22385787
[TBL] [Abstract][Full Text] [Related]
43. Diagnostic value of plasma and urinary 2-hydroxyglutarate to identify patients with isocitrate dehydrogenase-mutated glioma.
Lombardi G; Corona G; Bellu L; Della Puppa A; Pambuku A; Fiduccia P; Bertorelle R; Gardiman MP; D'Avella D; Toffoli G; Zagonel V
Oncologist; 2015 May; 20(5):562-7. PubMed ID: 25862748
[TBL] [Abstract][Full Text] [Related]
44. Monoallelic IDH1 R132H Mutation Mediates Glioma Cell Response to Anticancer Therapies via Induction of Senescence.
Zhan D; Ma D; Wei S; Lal B; Fu Y; Eberhart C; Laterra J; Ying M; Li Y; Meeker A; Lopez-Bertoni H; Xia S
Mol Cancer Res; 2021 Nov; 19(11):1878-1888. PubMed ID: 34348994
[TBL] [Abstract][Full Text] [Related]
45. IDH1 R132H mutation generates a distinct phospholipid metabolite profile in glioma.
Esmaeili M; Hamans BC; Navis AC; van Horssen R; Bathen TF; Gribbestad IS; Leenders WP; Heerschap A
Cancer Res; 2014 Sep; 74(17):4898-907. PubMed ID: 25005896
[TBL] [Abstract][Full Text] [Related]
46. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors.
Capper D; Weissert S; Balss J; Habel A; Meyer J; Jäger D; Ackermann U; Tessmer C; Korshunov A; Zentgraf H; Hartmann C; von Deimling A
Brain Pathol; 2010 Jan; 20(1):245-54. PubMed ID: 19903171
[TBL] [Abstract][Full Text] [Related]
47. Frequent false-negative immunohistochemical staining with IDH1 (R132H)-specific H09 antibody on frozen section control slides: a potential pitfall in glioma diagnosis.
Yoshida A; Satomi K; Ohno M; Matsushita Y; Takahashi M; Miyakita Y; Hiraoka N; Narita Y; Ichimura K
Histopathology; 2019 Jan; 74(2):350-354. PubMed ID: 30221786
[TBL] [Abstract][Full Text] [Related]
48. IDH Mutation Analysis in Glioma Patients by CADMA Compared with SNaPshot Assay and two Immunohistochemical Methods.
Urbanovska I; Megova MH; Dwight Z; Kalita O; Uvirova M; Simova J; Tuckova L; Buzrla P; Palecek T; Hajduch M; Dvorackova J; Drabek J
Pathol Oncol Res; 2019 Jul; 25(3):971-978. PubMed ID: 29556922
[TBL] [Abstract][Full Text] [Related]
49. Inhibition of Mutated Isocitrate Dehydrogenase 1 in Cancer.
Wu F; Cheng G; Yao Y; Kogiso M; Jiang H; Li XN; Song Y
Med Chem; 2018; 14(7):715-724. PubMed ID: 29792149
[TBL] [Abstract][Full Text] [Related]
50. IDH1-Mutation in Diffuse Gliomas in Persons Age 55 Years and Over.
Robinson C; Kleinschmidt-DeMasters BK
J Neuropathol Exp Neurol; 2017 Feb; 76(2):151-154. PubMed ID: 28110298
[TBL] [Abstract][Full Text] [Related]
51. Isocitrate Dehydrogenase 1 Expression in Canine Gliomas.
Fraser AR; Bacci B; le Chevoir MA; Long SN
J Comp Pathol; 2018 Nov; 165():33-39. PubMed ID: 30502793
[TBL] [Abstract][Full Text] [Related]
52. Expression Profile Analysis of Zinc Transporters (ZIP4, ZIP9, ZIP11, ZnT9) in Gliomas and their Correlation with IDH1 Mutation Status.
Kang X; Chen R; Zhang J; Li G; Dai PG; Chen C; Wang HJ
Asian Pac J Cancer Prev; 2015; 16(8):3355-60. PubMed ID: 25921144
[TBL] [Abstract][Full Text] [Related]
53. Spontaneous in vitro senescence of glioma cells confirmed by an antibody against IDH1R132H.
Stoczynska-Fidelus E; Och W; Rieske P; Bienkowski M; Banaszczyk M; Winiecka-Klimek M; Zieba J; Janik K; Rosiak K; Treda C; Stawski R; Radomiak-Zaluska A; Piaskowski S
Anticancer Res; 2014 Jun; 34(6):2859-67. PubMed ID: 24922649
[TBL] [Abstract][Full Text] [Related]
54. DZIP3 is a key factor to stratify IDH1 wild-type lower-grade gliomas.
Liang T; Zhou X; Li P; You G; Wang F; Wang P; Feng E
Aging (Albany NY); 2020 Nov; 12(24):24995-25004. PubMed ID: 33229627
[TBL] [Abstract][Full Text] [Related]
55. Expression of R132H mutational IDH1 in human U87 glioblastoma cells affects the SREBP1a pathway and induces cellular proliferation.
Zhu J; Cui G; Chen M; Xu Q; Wang X; Zhou D; Lv S; Fu L; Wang Z; Zuo J
J Mol Neurosci; 2013 May; 50(1):165-71. PubMed ID: 23011765
[TBL] [Abstract][Full Text] [Related]
56. Decreasing GSH and increasing ROS in chemosensitivity gliomas with IDH1 mutation.
Shi J; Sun B; Shi W; Zuo H; Cui D; Ni L; Chen J
Tumour Biol; 2015 Feb; 36(2):655-62. PubMed ID: 25283382
[TBL] [Abstract][Full Text] [Related]
57. IDH1(R132H) mutation causes a less aggressive phenotype and radiosensitizes human malignant glioma cells independent of the oxygenation status.
Kessler J; Güttler A; Wichmann H; Rot S; Kappler M; Bache M; Vordermark D
Radiother Oncol; 2015 Sep; 116(3):381-7. PubMed ID: 26328938
[TBL] [Abstract][Full Text] [Related]
58. Oncogenic MicroRNA-20a is downregulated by the HIF-1α/c-MYC pathway in IDH1 R132H-mutant glioma.
Xu Q; Ahmed AK; Zhu Y; Wang K; Lv S; Li Y; Jiang Y
Biochem Biophys Res Commun; 2018 May; 499(4):882-888. PubMed ID: 29625108
[TBL] [Abstract][Full Text] [Related]
59. Analysis of the IDH1 codon 132 mutation in brain tumors.
Balss J; Meyer J; Mueller W; Korshunov A; Hartmann C; von Deimling A
Acta Neuropathol; 2008 Dec; 116(6):597-602. PubMed ID: 18985363
[TBL] [Abstract][Full Text] [Related]
60. A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation.
Kato Y; Jin G; Kuan CT; McLendon RE; Yan H; Bigner DD
Biochem Biophys Res Commun; 2009 Dec; 390(3):547-51. PubMed ID: 19818334
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
